⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofuran SCHEMBL3405861 | 0.96 | ALDH1A1 (0.61) | — | |
| Tetrahydrofuran SCHEMBL28263987 | 0.96 | ALDH1A1 (0.61) | — | |
| Pyrrolidine SCHEMBL7216522 | 0.93 | ALDH1A1 (0.57) | — | |
| Tetrahydrofuran SCHEMBL27575002 | 0.93 | ALDH1A1 (0.57) | — | |
| SCHEMBL18856382 | 0.93 | ALDH1A1 (0.57) | — | |
| Pyrrolidine SCHEMBL27584439 | 0.93 | ALDH1A1 (0.57) | — | |
| Piperidine SCHEMBL15484966 | 0.89 | ALDH1A1 (0.60) | — | |
| SCHEMBL8748856 | 0.89 | ALDH1A1 (0.60) | — | |
| Piperidine SCHEMBL2415431 | 0.89 | ALDH1A1 (0.60) | — | |
| Azepane SCHEMBL28349218 | 0.89 | ALDH1A1 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813267-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-14 | — | — | US | claimed |
| US-20210069203-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-03-11 | — | — | US | claimed |
| US-20190255062-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-22 | — | — | US | claimed |
| US-10258627-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2019-04-16 | — | — | US | claimed |
| US-9359380-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-07 | — | — | US | claimed |
| US-20140275059-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | claimed |
| EP-3464249-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3233829-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | Pfizer Inc (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3157915-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | Pfizer Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-3096755-A2 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | Sova Pharmaceuticals, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| WO-2016097918-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2015193768-A1 | ARYL FUSED LACTAMS AS EZH2 MODULATORS | PFIZER INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193765-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2011156775-A2 | 8-(2'-HETEROCYCYL)PYRIDO[2.3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011138751-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | PFIZER INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-2032578-A2 | TRIAZOLOPYRIDAZINE DERIVATIVES | Pfizer Products Incorporated (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138472-A2 | TRIAZOLOPYRIDAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-1809621-A1 | METHODS OF PREPARING INDAZOLE COMPOUNDS | Pfizer, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2007023382-A2 | PYRIMIDINE AMINO PYRAZOLE COMPOUNDS, POTENT KINASE INHIBITORS | PFIZER INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006048744-A1 | METHODS OF PREPARING INDAZOLE COMPOUNDS | PFIZER INC. (US) | 2006-05-11 | — | — | WO | disclosed |